Back to Search
Start Over
[Brain imaging of Alzheimer' disease: state of the art and perspectives for clinicians].
- Source :
-
Revue medicale suisse [Rev Med Suisse] 2016 Apr 20; Vol. 12 (515), pp. 795-8. - Publication Year :
- 2016
-
Abstract
- To improve the clinical detection of Alzheimer's disease (AD) new diagnostic criteria have been proposed, based on biomarkers of synaptic dysfunction, AD-related neurodegeneration, and Aβ cerebral amyloidosis. Magnetic resonance imaging (MRI) and position emission tomography (PET) neuroimaging can be configured as powerful means for the detection of medial-temporal atrophy, reduced uptake of 18F-FDG PET or and increased retention of Aβ amyloid protein by amyloïd-PET. In this review, we will discuss these promising techniques that allow assessing in vivo AD pathology and help clinicians to better diagnose and follow-up patients, particularly in clinical trials using disease-modifying treatments.
- Subjects :
- Alzheimer Disease cerebrospinal fluid
Alzheimer Disease pathology
Amyloid beta-Peptides cerebrospinal fluid
Biomarkers cerebrospinal fluid
Fluorodeoxyglucose F18 administration & dosage
Humans
Image Interpretation, Computer-Assisted
Neuroimaging methods
Predictive Value of Tests
Radiopharmaceuticals administration & dosage
Sensitivity and Specificity
tau Proteins cerebrospinal fluid
Alzheimer Disease diagnosis
Brain pathology
Magnetic Resonance Imaging methods
Positron-Emission Tomography methods
Subjects
Details
- Language :
- French
- ISSN :
- 1660-9379
- Volume :
- 12
- Issue :
- 515
- Database :
- MEDLINE
- Journal :
- Revue medicale suisse
- Publication Type :
- Academic Journal
- Accession number :
- 27276723